Preclinical evaluation of a novel abluminal surface coated sirolimus eluting stent with biodegradable polymer matrix.
BACKGROUND
Second generation of drug eluting stents (DES) has attempted to improve safety using abluminal sirolimus drug delivery with biodegradable polymers matrix. The present preclinical study was designed to investigate the safety and efficacy profile of Abluminus™ stents (SES). This is a new coronary stent with sirolimus and biodegradable polymer matrix coated on abluminal stent and balloon surface.


METHODS
SES were compared with two controls: bare metal stent (BMS) and BMS + polymer coated stents (PC). All devices (40 stents) were implanted in porcine coronary arteries with primary endpoint of endothelialization at 7 days and subsequent histological and morphometric evaluations at 7, 30 and 90 days.


RESULTS
Early endothelialization at seven days was complete in all stents. Histology at 30 days revealed minimum inflammation in all groups and increased at 90 days in PC group while it was absent at 180 days. Thirty day morphometry showed significantly reduction of neointimal area in Abluminus™ (SES 0.96±0.48 mm(2); BMS 1.83±0.34 mm(2); PC 1.76±0.55 mm(2); P<0.05); after 90 days neointimal area was 1.10±0.54 mm(2) for SES; 1.92±0.36 mm(2) for BMS; and 1.94±0.48 mm(2) for PC; P<0.05). Neointimal thickness at 30 and 90 days respectively was 0.15±0.07 and 0.18±0.10 mm for SES, 0.57±0.08 and 0.61±0.09 mm for BMS and 0.52±0.09 and 0.59±0.08 mm, P<0.001 for PC group.


CONCLUSIONS
The most significant experimental evidence appears to be earlier endothelialization at 7 days for SES which led to safety of the device. Efficacy of the device was also observed by a reduced neointimal thickness and minimized inflammatory score at all follow-ups. Termination of antiplatelet at 30 days has not shown any further complications. Polymer thickness was almost in negligible amount at 180 days with no inflammation.
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Prakash
P
Sojitra
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Manish
M
Doshi
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Marco
M
Galloni
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Christina
C
Vignolini
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Ashwin
A
Vyas
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Bhavesh
B
Chevli
1 Envision Scientific Private Limited, Surat, Gujarat 395001, India ; 2 Life and Device S.r.l., Spin-Off of University of Turin, Turin, Italy ; 3 University of Turin, Turin, Torino, Italy.
Imad
I
Sheiban
Stent; abluminal; bio-degradable polymer; restenosis